JPET # 263434 Introduction
The Wnt/β-catenin signaling cascade is a highly conserved pathway and essential for embryonic development, stem cell maintenance and tissue homeostasis. The dysregulation of the Wnt/β-catenin pathway by mutations and epigenetic changes is frequently found in various human cancers including breast cancer (MacDonald et al., 2009; Clevers and Nusse, 2012; Nusse and Clevers, 2017; Krishnamurthy and Kurzrock, 2018) . The transcriptional coactivator β-catenin is a core component of the pathway, whose protein level and activity are closely controlled by a destruction complex in the cytoplasm. This complex is composed of the scaffolding protein AXIN, the adenomatous polyposis coli (APC) protein, casein kinase 1α (CK1α), glycogen synthase kinase 3β (GSK3β), and beta-transducin repeats-containing proteins (β-TrCP).
Wnt/β-catenin signaling is initiated by binding of Wnt ligands to their transmembrane receptors of the Frizzled (FZD) family and the low density lipoprotein receptor-related protein 5/6 (LRP5/6). Subsequently, CK1ɛ is activated and phosphorylates Dishevelled (DVL). Receptor complexes further induce the formation of LRP6 signalosomes, resulting in the phosphorylation of LRP6 at multiple sites via distinct kinases, which triggers the downstream cascade that leads to β-catenin stabilization. Finally, free βcatenin accumulates in the cytoplasm which allow it to translocate to the nucleus, and then β-catenin interacts with the T-cell factor/lymphoid-enhancing factor (TCF/LEF) transcription factors to initiate transcription of Wnt target genes (MacDonald et al., 2009; Clevers and Nusse, 2012) .
Triterpenoids are a large family of structurally-related compounds biosynthesized in some plants by the cyclization of squalene. Oleanolic acid (3b-hydroxyolean-12-en-28-oic acid, OA) is a naturally occurring triterpenoid which exhibits antioxidant, antibacterial, antifungal, anticancer, and anti-inflammatory activities (Supplemental Figure 1A ) (Ayeleso et al., 2017) . To improve the pharmacological efficacy of OA, syntheses of a series of novel derivatives have been conducted, including 2-cyano-3, 12-dioxooleana-1, 9(11)-dien-28-oic acid (CDDO), CDDO-imidazolide (CDDO-Im) and CDDO methyl ester (CDDO-Me) (Supplemental Figure 1A) . Among them, were obtained from the American Type Culture Collection (ATCC, Manassas, VA).
HEK293T, L, L-Wnt3A and Hs578T cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) (Gibco, Tennessee, USA) and 1% penicillin-streptomycin (Gibco, Tennessee, USA) in a humidified incubator at 37 °C with 5% CO2. As described previously, Wnt3A conditioned medium (Wnt3A-CM) and control conditioned medium were prepared (Willert et al., 1999) . MDA-MB-231 and MDA-MB-468 cells were maintained in Leibovitz's L-15 medium (Gibco, Tennessee, USA) supplemented with 10% FBS and 1% penicillin-streptomycin in a humidified incubator at 37 °C without CO2.
Luciferase Reporter Assays
HEK293T cells were cultured in 24-well plates and then transiently transfected using Lipofectamine 2000 (Invitrogen, California, USA) in sixtuplicate with 0.25 μg of luciferase reporter plasmid, 50 ng of control plasmid pCMXβgal, and 50-200 ng of the indicated expression vectors according to the manufacturer's instructions. After 24 h, the cells were incubated with the indicated concentrations of compounds. In some experiments, cells were treated with Wnt3A-CM or control conditioned medium together with the compounds as indicated in the figure legends. Luciferase activity was measured with the Luciferase Assay System (Promega, Wisconsin, USA) and normalized using β-gal activity as an internal control.
Immunoblot Analyses
Protein samples were extracted from cells or tumor tissues using lysis buffer containing 20 mM Tris· HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, protease inhibitor cocktail (HY-K0010, MedChemExpress, New Jersey, USA), 
Ubiquitination assays
HEK293T cells co-transfected with indicated expression plasmids were treated with the indicated concentrations of CDDO-Me for 24 h. Cells were lysed with lysis buffer containing 20 mM Tris· HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, protease inhibitor cocktail (HY-K0010, MedChemExpress, New Jersey, USA), phosphatase inhibitor cocktail (HY-K0021, MedChemExpress, New Jersey, USA) and 1 mM PMSF after treatment with 10 μM MG132 for 6 h. The supernatant fractions were collected by centrifugation at 12,000 rpm for 15 min and subjected to immunoprecipitation using anti-V5 or anti-Flag M2 Sepharose followed by Western blotting using specific antibodies as indicated. The antibodies used were listed in Supplemental Table 1 .
Real-time PCR Analyses
Total RNA from cells or tumor tissues was isolated using RNAiso Plus Reagent (TaKaRa) and then reverse-transcribed into cDNA using the Primescript RT Reagent Kit (TaKaRa) according to the manufacturer's instructions. Real-time PCR assays were performed using an ABI Prism 7300 Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) with 2× SYBR Green qPCR Master Mix (Promega). The comparative Ct method was used to analyze relative expression of genes. The primers were listed in Supplemental Table 2 . This article has not been copyedited and formatted. The final version may differ from this version.
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8 Colony Formation Assays 1 × 10 3 cells/well were grown in medium containing 10% FBS in 6-well plates overnight, and then the indicated concentrations of CDDO-Me were added into the medium. The cells were cultured in a humidified incubator at 37 °C with 5% CO2 for 10 days and then the colonies were fixed with 4% paraformaldehyde, stained with 0.1% crystal violet and photographed. Then the colonies were counted and quantified.
Cell Viability and Proliferation Assays
Cells were seeded onto 96-well plates at a density of 2 × 10 4 cells/well and cultured overnight. The cells were then treated with DMSO or serially diluted CDDO-Me for 24 h or 48 h. For viability assay, the cells were incubated with fresh medium containing 0.5 mg/mL MTT for another 4 h. Then the medium was removed and formazan crystals were dissolved in DMSO and the absorbance was measured at 570 nm. To examine the cell proliferation, the BrdU incorporation assay was carried out using the Cell Proliferation ELISA BrdU Chemiluminescent Kit (Roche) as directed by the manufacturer's instruction.
Immunofluorescence analyses
FZD7-Alexa Fluor TM 594 antibody was generated by conjugating FZD7 antibody to Alexa Fluor TM 594 using Zenon™ Alexa Fluor™ 594 Human IgG Labeling Kit (Invitrogen, Z25407) according to the manufacturer's instructions. The cells were incubated with 0.1 μM FZD7-Alexa Fluor TM 594 antibody for 30 min on ice followed by washing twice with PBS. The cells were then treated with 0.4 μM CDDO-Me for 3.5 h in an incubator before adding 60 nM LysoTracker™ Deep Red (Invitrogen, L12492) for 30 min. After fixing with 4% paraformaldehyde, DAPI was used for visualization of cell nucleus. Sections were observed by using a Leica TM laser scanning confocal microscope.
Sphere formation assays
Ultra-low attachment 24-well plates (Corning) were chosen to culture unattached This article has not been copyedited and formatted. The final version may differ from this version.
JPET Fast Forward. Published on February 3, 2020 as DOI: 10.1124/jpet.119.263434 at ASPET Journals on February 29, 2020 jpet.aspetjournals.org Downloaded from JPET # 263434 9 spheroid cells. Hs578T cells were seeded as single cells into the sphere culture medium MammCult (STEMCELL technologies) supplemented with 0.48 μg/ml hydrocortisone and 4 μg/ml heparin in the presence or absence of the indicated amounts of CDDO-Me.
After 10 days incubation, spheres with diameter over 50 µm were counted and representative fields were microphotographed.
Xenograft Mouse Model and treatment with CDDO-Me
All animal experiments were performed according to the protocols approved by the Laboratories and female BALB/c nude mice were obtained from Shanghai SLAC Laboratory Animal Co., Ltd. After the breast tumors grew to ∼500 mm 3 , the MMTV-Wnt1 mice were sacrificed and tumor fragments were implanted s.c. into BALB/c nude mice. When the tumors reached ∼50 mm 3 , the mice were randomly divided into two groups and treated by i.p. injection with the vehicle (0.8% DMSO/12% Cremophor/8% ethanol in normal saline) or 5 mg/kg CDDO-Me in vehicle twice weekly. Subsequently, tumor volumes were measured with a caliper and calculated using the following formula: 0.52 × length × width 2 . When tumor size reached 15 mm in diameter or tumors showed signs of ulceration, CO2 euthanasia were performed. The tumors were then excised, weighed and photographed.
Histological Analyses
The tumors were fixed in formalin, embedded with paraffin, and sectioned.
Hematoxylin and eosin staining and immunohistochemistry analysis were carried out as previously described (Wang et al., 2016) . The primary antibodies used were listed in Supplemental Table 1 .
Statistical Analyses
Statistical analyses were carried out using Student's t test or one-way ANOVA followed by a Dunnett-t test. Results are presented as mean ± SEM. A P value less than 0.05 was This article has not been copyedited and formatted. The final version may differ from this version. 
Results
Inhibition of Wnt/β-catenin Signaling by CDDO-Me
An initial screen of a FDA-approved drug library was performed in HEK293T cells using a 96-well plate-based SuperTOPFlash reporter system, in which Wnt3A-CM was used to activate the Wnt/β-catenin pathway. The screen identified OA, CDDO and CDDO-Me as antagonists of Wnt/β-catenin signaling. Previous studies have identified these three compounds as Nrf2 activators and NF-κB inhibitors (Ahmad et al., 2006; To et al., 2015; Xu et al., 2017; Zagorski et al., 2018) . Concerning the importance of the Wnt/β-catenin signaling pathway in initiation and progression of various cancers (Nusse and Clevers, 2017; Mirabelli et al., 2019; Zhong and Virshup, 2019) , we characterized the antagonistic effect of these three compounds on Wnt/β-catenin signaling.
In order to prove the Wnt inhibitory effect of CDDO-Me, a SuperTOPFlash reporter plasmid was transfected into HEK293T cells along with Wnt1, LRP6, Wnt1/LRP6, FZD5/LRP6, FZD7/LRP6, DVL2, and β-catenin expression plasmids, respectively. CDDO-Me dose-dependently inhibited the transcriptional activity of Wnt signaling activated by Wnt1, LRP6, Wnt1/LRP6, FZD5/LRP6, and FZD7/LRP6 (Fig. 1A-E). The increased transcriptional activity induced by the Wnt3A-conditioned medium (Wnt3A-CM) was also blocked by CDDO-Me ( Fig. 1H ). However, CDDO-Me did not inhibit the SuperTOPFlash activity induced by either DVL2 or β-catenin (Fig. 1F and G) , suggesting that CDDO-Me may act on the upstream elements of DVL2 and β-catenin. In control experiments, CDDO-Me at Wnt inhibitory concentrations did not suppress YAP-mediated activation of a Hippo reporter (8x GTIIC-Luc) ( Fig. 1I) , indicating that the Wnt inhibitory effect of CDDO-Me is specific.
We also evaluated the effects of CDDO-Me analogues CDDO and OA on Wnt/βcatenin signaling using a SuperTOPFlash reporter assay. CDDO and OA inhibited Wnt These results suggest that CDDO-Me, CDDO and OA may inhibit Wnt/β-catenin signaling by a common mechanism.
CDDO-Me inhibits Wnt/β-catenin signaling in HEK293T cells
To investigate the mechanism underlying Wnt signaling inhibition by CDDO-Me, the Wnt/β-catenin signaling cascade was activated by either co-transfection with a Wnt1 expression plasmid or treatment with Wnt3A-CM in HEK293T cells. As shown in Fig.   2 , Wnt1 expression or Wnt3A-CM increased phosphorylation of LRP6 and DVL2, resulting in increased protein levels of active β-catenin and total β-catenin ( Fig. 2A and   B ). Treatment with CDDO-Me markedly reduced the levels of phosphorylated LRP6, total LRP6, phosphorylated DVL2, active β-catenin and total β-catenin in the cells transfected with Wnt1 ( Fig. 2A) or treated with Wnt3A-CM ( Fig. 2B ). Similar to CDDO-Me, CDDO and OA also downregulated the levels of phosphorylated LRP6, total LRP6, phosphorylated DVL2, active β-catenin and total β-catenin in the cells either transfected with Wnt1 expression vector (Supplemental Figure 2A 
CDDO-Me suppresses Wnt/β-catenin signaling in breast cancer cells
To assess the effect of CDDO-Me on Wnt/β-catenin signaling in breast cancer cells， 
CDDO-Me induces the degradation of LRP6/FZD7 receptor complex
To investigate whether CDDO-Me-induced downregulation of LRP6 and FZD7 was a consequence of decreased transcription, the real-time PCR assay was performed. Breast cancer Hs578T and MDA-MB-231 cells were treated with different concentrations of CDDO-Me for 24 h. We did not observe any significant decrease in mRNA expression of LRP6 and FZD7 after CDDO-Me treatment in both cell lines ( Fig. 4A and B) , 
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13 treatment with bafilomycin A1, but it was not restored by MG132 ( Fig. 4C and D) .
Consistently, we observed an increased lysosomal accumulation of FZD7 following CDDO-Me treatment in HEK293T cells (Fig. 4E) . These results indicate that the CDDO-Me-induced degradation of LRP6 and FZD7 is mediated by the lysosomal pathway rather than the proteasome pathway.
To determine if CDDO-Me could increase LRP6 or FZD7 ubiquitination, HEK293T cells transfected with either LRP6-V5 or FZD7-Flag expression plasmids together with expression vector for myc-ubiquitin (Ub) were treated with CDDO-Me, and the cell lysates were subjected to immunoprecipitation using anti-Ub and anti-V5 or anti-Flag antibodies. As shown in Fig. 4F and G, CDDO-Me treatment increased the ubiquitination of LRP6 or FZD7 ( Fig. 4F and G) .
CDDO-Me induces FZD7 degradation in a LRP6 ectodomain-dependent manner
Interestingly, we noted that CDDO-Me failed to induce the degradation of FZD7 in LRP6-knockdown Hs578T cells (Fig. 5A) . Similar results were observed in MDA-MB-231 cells (Fig. 5B) . These results suggest that CDDO-Me-induced FZD7 degradation may be mediated by LRP6 in breast cancer cells.
To evaluate the role of LRP6 ectodomain in CDDO-Me-induced FZD7 degradation, a LRP6 mutant lacking the N-terminal extracellular domain (LRP6ΔN) was constructed ( Fig. 5C) (Su et al., 2018) . HEK293T cells were transfected with expression plasmids encoding LRP6 or LRP6ΔN. As expected, LRP6ΔN constitutively activated Wnt/βcatenin signaling. CDDO-Me treatment did not exert any inhibitory effect on transcriptional activity induced by LRP6ΔN ( Fig. 5C ), suggesting the extracellular domain of LRP6 is required for CDDO-Me-induced degradation of FZD7. Consistent with this, CDDO-Me could not induce FZD7 degradation in the presence of LRP6ΔN ( Fig. 5D and E) . Furthermore, in vitro ubiquitination experiments showed that CDDO-Me had little effect on the ubiquitination of FZD7 in the presence of LRP6ΔN ( Fig. 5F and G). 
CDDO-Me inhibits the Wnt/β-catenin pathway and induces the degradation of LRP6 and FZD7 in an α, β-unsaturated carbonyl moiety-independent manner
To assess whether the Wnt inhibitory effect of CDDO-Me is dependent on its α,βunsaturated carbonyl group, we examined the effect of CDDO-Me on Wnt/β-catenin signaling and LRP6/FZD7 receptor complex in the presence of NAC. NAC possesses a reactive free thiol group and can interact with the α,β-unsaturated carbonyl moiety of CDDO-Me. Our results revealed that the presence of NAC had no effect on CDDO-Me-induced inhibition of SuperTOPFlash reporter activity (Fig. 6A) , compoundinduced degradation of exogenous LRP6 and FZD7 in HEK293T cells ( Fig. 6B and C) and compound-induced degradation of endogenous LRP6 and FZD7 in Hs578T and MDA-ME-231 cells ( Fig. 6D and E ). Meanwhile, we tested the effect of NAC on ethacrynic aid (EA)-mediated Wnt inhibition. EA contains an α,β-unsaturated carbonyl unit and is a known antagonist of the Wnt/β-catenin pathway (Jin et al., 2009; Lu et al., 2009 ). Our result showed NAC could prevent EA-mediated effects on the Wnt/βcatenin pathway (Fig. 6A ).
CDDO-Me inhibits the Wnt/β-catenin pathway in a GSK3β independent manner
GSK3β is a serine/threonine kinase involved in multiple cellular responses, including modulation of β-catenin stability. Its kinase activity is negatively regulated by phosphorylation of GSK3β at Ser9. A previous study reported that apoptotic doses of CDDO-Me (1-2.5 μM) could induce inactivating phosphorylation at Ser9 of GSK3β in prostate cancer cells (Vene et al., 2008) . Our results showed that CDDO-Me at nanomolar or low micromolar concentrations (100 nM-500 nM) had little effect on phosphorylation at Ser9 of GSK3β in Hs578T cells (Supplemental Figure 5) , while increased phosphorylation at Ser9 of GSK3β was observed after treatment with 1 μM CDDO-Me in Hs578T cells. These results suggest that the antagonistic effect of CDDO-Me on Wnt/β-catenin signaling was independent of GSK3β. Figure 6C ). We further assessed the colony-forming ability of breast cancer cells using cell colony formation assay. As shown in Fig. 7A , CDDO-Me markedly repressed the clonogenic ability of Hs578T and MDA-MB-231 ( Fig. 7A ).
CDDO-Me represses cell viability, proliferation, colony formation and stemness in breast cancer cells
Since Wnt/β-catenin signaling plays a critical role in cancer stem cell (CSC) maintenance, we used the sphere formation assay in vitro to evaluate the effect of CDDO-Me on CSC self-renewal potential. Nanomolar concentrations of CDDO-Me significantly reduced tumorsphere formation in Hs578T cells (Fig. 7B) . Given the role of Wnt/β-catenin signaling in the regulation of expression of CSC marker genes, we examined the effect of CDDO-Me on the expression of CSC marker genes LGR5, Oct4, Snail and Slug. Real-time PCR and immunoblotting revealed that CDDO-Me treatment decreased the mRNA and protein levels of CSC markers LGR5, Oct4, Snail and Slug ( Fig. 7C and D) .
CDDO-Me inhibits the growth of MMTV-Wnt1 tumor allografts via the downregulation of Wnt/β-catenin signaling
We tested the antitumor efficacy of CDDO-Me against MMTV-Wnt1 tumor allografts.
The primary MMTV-WNT1 tumors were fragmented and s.c. implanted into BALB/c nude mice. Once the tumors reached approximately 50 mm 3 , mice were i.p. injected with either vehicle or 5 mg/kg CDDO-Me twice a week for 3 weeks. CDDO-Me administration arrested tumor growth ( Fig. 8A-C) . The treatment regimen was welltolerated and did not cause significant weight loss (data not shown). Histological This article has not been copyedited and formatted. The final version may differ from this version.
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JPET # 263434 16 analyses showed that CDDO-Me treatment reduced tumor cell density and proliferation as assessed by Ki-67 staining (Fig. 8D and E) .
To investigate whether CDDO-Me-induced inhibition of tumor growth was accompanied with the suppression of Wnt/β-catenin signaling, the tumor tissues from the control and treatment groups were examined using immunohistochemical (IHC) staining, immunoblot analyses, and real-time PCR. Administration of CDDO-Me noticeably reduced the expression of active and total β-catenin (Fig. 8E) . The CDDO-Me-treated tumors exhibited markedly decreased levels of phosphorylated and total LRP6, phosphorylated and unphosphorylated DVL2, and CSC-related markers Snail, Slug, Oct4 and LGR5, compared to the vehicle treated tumors (Fig. 8F) . Moreover, the expression levels of Wnt target genes Fibronectin, Survivin, Snail, Slug, Oct4 and
LGR5 were significantly reduced in tumors from mice treated with CDDO-Me (Fig.   8G ).
Discussion
Although genetic mutations in the genes encoding intracellular components of Wnt signaling are rare, aberrant activation of this signaling pathway is frequently observed in human breast cancer. Accumulating evidence indicates that dysregulation of cell surface Wnt signaling components may contribute to constitutive activation of this pathway in breast cancer (Lamb et al., 2013; Pohl et al., 2017; Zhan et al., 2017) . The Wnt signaling co-receptor LRP6 has been shown to be upregulated in a subset of human breast cancer tissues and cell lines . Knockdown of LRP6 in breast cancer cells significantly decreased Wnt/β-catenin signaling, cell proliferation, and tumor growth in vivo . Notably, overexpression of LRP6 in mammary epithelial cells driven by the MMTV promoter is sufficient to induce mammary gland hyperplasia (Zhang et al., 2010) . The Wnt receptor FZD7 also plays a critical role in cell proliferation in triple negative breast cancer. Yang et al reported that FZD7 was overexpressed in triple negative breast cancer tissues and cell lines (Yang et al., 2011) .
Downregulation of FZD7 in breast cancer cells resulted in impaired cell growth and
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JPET Fast Forward. Published on February 3, 2020 as DOI: 10.1124/jpet.119.263434 at ASPET Journals on February 29, 2020 jpet.aspetjournals.org Downloaded from tumor transformation (Yang et al., 2011) . In vivo studies revealed that FZD7 shRNA induced growth retardation via blocking the Wnt/β-catenin signaling pathway (Yang et al., 2011) . These studies prove the concept that LRP6 and FZD7 may serve as potential therapeutic targets for the treatment of breast cancer. Inhibition of either Cancer stem cells (CSCs) are a small population of tumor cells responsible for tumor initiation, recurrence, metastasis and drug resistance in multiple tumor types (Agliano et al., 2017; Phi et al., 2018) . Several key developmental signaling pathways, such as Wnt, Notch and Hedgehog, are required for maintaining the stemness of CSCs.
In human breast cancer, the CD44 + CD24 −/low Lineage − cells were originally identified as CSCs. As few as 100 of these cells were able to form tumors in the NOD/SCID mice (Al-Hajj et al., 2003) . Other cellular surface markers, such as CD133, CD166, epithelial cell adhesion molecule (EpCAM) and aldehyde dehydrogenase (ALDH), have also been used for the isolation of breast CSCs (Xia, 2014; Saeg and Anbalagan, 2018) .
CDDO-Im is an imidazole-containing oleanane triterpenoid. This compound has been
shown to inhibit the tumorsphere formation of breast cancer SUM159 cells. Moreover, CDDO-Im could suppress the CD44 + /CD24 −/low /EpCAM + cells in SUM159 tumorspheres (So et al., 2014) . The present study demonstrated that CDDO-Me markedly inhibited tumorsphere formation in breast cancer Hs578T cells, and resulted in the downregulation of CSC marker genes LGR5, Oct4, Snail and Slug via antagonizing Wnt/β-catenin signaling. Importantly, the administration of CDDO-Me reduced the expression of CSC marker genes LGR5, Oct4, Snail and Slug in a Wnt1driven murine mammary tumor model. These results indicate that CDDO-Me may exhibit its anti-breast cancer activity through targeting breast CSCs.
In conclusion, CDDO-Me could directly bind to the extracellular domain of LRP6 and induce lysosomal degradation of LRP6/FZD7 receptor complex, resulting in the downregulation of Wnt/β-catenin signaling in vitro and in vivo (Fig. 9) . In a MMTV-Wnt1 xenograft model, CDDO-Me significantly suppressed tumor growth via the inhibition of Wnt/β-catenin signaling. These results indicate that the anti-breast cancer activity of CDDO-Me is associated with its antagonistic effect on the Wnt/β-catenin signaling cascade. 
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